- Home
- BKYI vs MBRX Comparison
BKYI vs MBRX Comparison
Compare BKYI & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKYI | MBRX |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 6.1M |
| IPO Year | 2013 | 2016 |
Fundamental Metrics
Financial Performance| Metric | BKYI | MBRX |
|---|---|---|
| Price | $0.57 | $2.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | ★ 190.8K | 115.9K |
| Earning Date | 05-14-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,302,984.00 | N/A |
| Revenue This Year | $7.45 | N/A |
| Revenue Next Year | $23.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 111.81 | N/A |
| 52 Week Low | $0.51 | $0.25 |
| 52 Week High | $1.97 | $7.98 |
Technical Indicators
Market Signals| Indicator | BKYI | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 47.07 |
| Support Level | $0.53 | $0.37 |
| Resistance Level | $0.63 | $5.15 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 6.75 | 82.76 |
Price Performance
Historical ComparisonAbout BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.